Search PubMed⌕ Search

Biomedical subjects

A Ayub

Publications and source records attributed to A Ayub.

21 records · Page 2Linked to original sources

Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).

The antimicrobial activity of the new fluoroquinolone rufloxacin (MF 934) was evaluated by a standardized agar dilution method against recent clinical isolates of Salmonella typhi (67 strains) and Brucella melitensis (108 isolates). The results were compared with 5 other commercially available or investigational fluoroquinolones. All the isolates of S. typhi were inhibited by 1.0 mg/l of rufloxacin as compared to 4-8 mg/l for B. melitensis. Minimum inhibitory concentrations of rufloxacin against both S. typhi and B. melitensis were 4-16 times higher than those of other fluoroquinolones.

Anti-Infective Agents↗

Comparative in vitro activity of Ro 09-1428, a novel cephalosporin with a catechol moiety.

The in vitro activity of Ro 09-1428, a new parenteral cephalosporin, was compared with that of other beta-lactams and aminoglycosides in 1230 clinical isolates from 1028 consecutive patients. Using an agar dilution method, the drugs were tested against 625 isolates of Enterobacteriaceae, 68 Pseudomonas aeruginosa, 36 Xanthomonas maltophilia, 20 Aeromonas hydrophila, 54 Acinetobacter, 373 staphylococci, and 54 strains of enterococci. More than 98% of Enterobacteriaceae were susceptible to Ro 09-1428, with a minimal inhibitory concentration of less than 0.03 to 4.0 micrograms/ml. Ro 09-1428 also inhibited 99% and 72% of the clinical isolates of P aeruginosa and X maltophilia, respectively. All isolates of methicillin-susceptible Staphylococcus aureus (MSSA) were susceptible to this cephalosporin. However, only 46% of the 54 strains of enterococci exhibited in vitro susceptibility. Ro 09-1428 was found to be superior or comparable to most penicillins, cephalosporins, and aminoglycosides against both gram-negative bacteria and MSSA.

Aminoglycosides↗